Article Text

Download PDFPDF
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy
  1. Marta Zola1,
  2. Alejandra Daruich1,2,3,
  3. Alexandre Matet1,4,5,
  4. Irmela Mantel1,
  5. Francine Behar-Cohen2,6
  1. 1 Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland
  2. 2 INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France
  3. 3 Ophthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
  4. 4 Department of Ophthalmology, Institut Curie, PSL Research University, Paris, France
  5. 5 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  6. 6 Ophthalmology Department, Cochin Hospital, AP-HP, Paris, France
  1. Correspondence to Dr Francine Behar-Cohen, INSERM, UMRS1138, Team 17, From Physiopathology of Ocular Diseases to Clinical Development, Université Sorbonne Paris Cité, Centre de Recherche des Cordeliers, Paris 75006, France; francine.behar{at}


Aims To evaluate the long-term oral mineralocorticoid receptor antagonist (MRa) treatment in chronic central serous chorioretinopathy (CSC).

Methods Patients with chronic non-resolving CSC (defined as foveal subretinal fluid (SRF) lasting >4 months with retinal pigment epithelium (RPE) alterations) treated with MRa only (eplerenone or spironolactone) for at least 6 months were retrospectively included. Clinical and imaging characteristics were recorded during visits at baseline, 6, 12, 18 and 24 months.

Results Sixteen eyes of 16 patients were included (mean age 53±11 years; 14 men, 2 women). Mean duration of SRF before treatment initiation was 11.2±19.7 months. MRa treatment was administered during 21.0±5.1 months (range, 10–24 months). There was a progressive improvement of visual acuity (p=0.05), a decrease of foveal SRF height (p=0.011), central macular thickness (p=0.004) and subfoveal choroidal thickness (p=0.002) over 24 months. Changes in SRF were correlated with subfoveal choroidal thickness at 24 months (p=0.006, Spearman r=065). The mean time to complete foveal SRF resolution was 10.5±8.0 months after treatment initiation. At 24 months, foveal SRF resolution was achieved in 13 eyes (81%). Minor side effects occurred in five patients (31%) and resolved after switching between MRa.

Conclusion The visual and anatomical benefit of MRa treatment prolonged for 6 months or more in chronic, non-resolving CSC appeared to be maintained over a 24-month period. These results suggest that MRa can be proposed as an alternative therapy in severe CSC with advanced RPE alterations.

  • retina
  • treatment medical

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • MZ and AD contributed equally.

  • Contributors AD, AM and FB-C were involved in the conception and design of the work. MZ, AD, AM and IM were involved in the acquisition and analysis of data for the work. MZ, AD, AM, IM and FB-C were involved in the interpretation of data. MZ and AD drafted the manuscript. AM, IM and FB-C critically reviewed the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of the Swiss Federal Department of Health.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Keith Barton Jost B Jonas James Chodosh